Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure
Subodh Verma(St. Michael's Hospital), Francesco Cosentino(Linköping University), Arjun Pandey(University of Ottawa), Nitish K. Dhingra(St. Michael's Hospital)
Cited by 11
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
|European Heart Journal|2013|1.4k
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
|European Heart Journal|2023|1.4k
New Markers of Inflammation and Endothelial Cell Activation
|Circulation|2003|733